Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- PER.AU
- Price
- 0.01
- Stock movement up
- +- (%)
- Company name
- Percheron Therapeutics Ltd
- Exchange
- (AU ,
- Currency
- AUD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 8.70M
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -89.87%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-10-31
DIVIDENDS
PER.AU does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.01 |
| Daily high | 0.01 |
| Daily low | 0.01 |
| Daily Volume | 1.79M |
| All-time high | 0.34 |
| 1y analyst estimate | 0.01 |
| Beta | 0.89 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| PER.AU | S&P500 | |
| Current price drop from All-time high | -97.61% | -1.10% |
| Highest price drop | -97.91% | -19.00% |
| Date of highest drop | 17 Feb 2025 | 8 Apr 2025 |
| Avg drop from high | -93.10% | -2.76% |
| Avg time to new high | - | 5 days |
| Max time to new high | 270 days | 89 days |
COMPANY DETAILS
Marketcap
8.70M
Marketcap category
Small-cap
Description
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company's lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also develops HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed Phase I clinical trial to targer v-domain immunoglobulin suppressor of T-cell activation and cancer cells. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
Australia
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found